Is Most-Watched Stock Novo Nordisk A/S (NVO) Worth Betting on Now?

Core Viewpoint - Novo Nordisk's stock has experienced a decline of -2.2% over the past month, underperforming the Zacks S&P 500 composite's -0.5% change and the Zacks Large Cap Pharmaceuticals industry's -2% loss, raising questions about its near-term performance [1] Earnings Estimate Revisions - The consensus earnings estimate for the current quarter is $0.91 per share, reflecting a year-over-year increase of +9.6%, with a recent change of +2.2% over the last 30 days [4] - For the current fiscal year, the consensus earnings estimate is $3.85, indicating a +17.4% change from the previous year, with a +1.3% change in the last 30 days [4] - The next fiscal year's consensus earnings estimate is $4.71, showing a +22.4% change from the prior year, with a +2.1% change over the past month [5] - Novo Nordisk holds a Zacks Rank 3 (Hold), influenced by recent changes in consensus estimates and other earnings-related factors [6] Revenue Growth Forecast - The consensus sales estimate for the current quarter is $11.33 billion, indicating a year-over-year increase of +19.1% [10] - The sales estimates for the current and next fiscal years are $50.66 billion and $58.15 billion, reflecting changes of +20.3% and +14.8%, respectively [10] Last Reported Results and Surprise History - In the last reported quarter, Novo Nordisk achieved revenues of $12.26 billion, a year-over-year increase of +28.9%, and an EPS of $0.91 compared to $0.71 a year ago [11] - The reported revenues exceeded the Zacks Consensus Estimate of $11.34 billion by +8.11%, and the EPS surprise was +9.64% [11] - Over the last four quarters, Novo Nordisk surpassed consensus EPS estimates twice and revenue estimates twice [12] Valuation - Novo Nordisk is graded B in the Zacks Value Style Score, indicating it is trading at a discount to its peers [16]